Peer-reviewed data shows Gilead's drug helps COVID-19 recovery time

(Reuters) - The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s (GILD.O) remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.